| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $89.1M | +36.1% |
| Cost of Revenue | $10.8M | +24.1% |
| Gross Profit | $78.3M | +37.9% |
| R&D Expense | $19.1M | +41.2% |
| SG&A Expense | $44.5M | +31.3% |
| Operating Income | -$58.4M | -47.1% |
| Pre-tax Income | -$53.4M | -32.0% |
| Income Tax | $0 | — |
| Net Income | -$53.4M |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $40.5M | -79.2% |
| Short-term Investments | $118.8M | — |
| Accounts Receivable | $15.1M | +38.4% |
| Inventory | $7.3M | +5.1% |
| Current Assets | $186.7M | -14.1% |
| Total Assets | $195.8M | -13.1% |
| Current Liabilities | $19.2M | +47.7% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$40.8M | -16.5% |
| Capital Expenditures | $767K | -42.8% |
| Investing Cash Flow | -$118.1M | -7292.8% |
| Financing Cash Flow | $5.1M | -97.4% |
| Free Cash Flow | -$41.6M | -14.3% |
| -32.0% |
| EPS (Basic) | -$1.46 | +56.9% |
| EPS (Diluted) | -$1.46 | +56.9% |
| Total Liabilities |
| $40.5M |
| +18.2% |
| Stockholders' Equity | $155.3M | -18.7% |